Development of a preventive vaccine for filovirus infection in primates
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsGary J. Nabel, Zhi-yong Yang, Nancy Sullivan, Anthony Sanchez
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to viral vaccines and, more specifically, to filovirus vaccines and methods of eliciting an immune response against a filovirus or disease caused by infection with filovirus.
Claims9
A vaccine comprising an adenoviral vector comprising a sequence encoding Ebola Sudan glycoprotein being at least 95% identical to Ebola Sudan glycoprotein that is encoded in the construct VRC6601 (SEQ ID NO:26).
A composition for boosting an immune response to a viral antigen in an individual, comprising an adenoviral vector comprising a sequence encoding Ebola Sudan glycoprotein being at least 95% identical to Ebola Sudan glycoprotein that is encoded in the construct VRC6601 (SEQ ID NO:26).
A method for boosting an immune response to a viral antigen in an individual, comprising administering to the individual a composition comprising an adenoviral vector comprising a sequence encoding Ebola Sudan glycoprotein being at least 95% identical to Ebola Sudan glycoprotein that is encoded in the construct VRC6601 (SEQ ID NO:26).
Dependencies are inferred from the claim text.